Merck's Keytruda Drives its 2025 Revenue Surge: What's Ahead? [Yahoo! Finance]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Yahoo! Finance
Merck MRK has a strong foothold in the oncology market, primarily supported by its biggest revenue driver, Keytruda. The blockbuster PD-1 inhibitor accounts for around 55% of the company's pharmaceutical sales and has played an instrumental role in driving Merck's steady revenue growth over the past few years. Keytruda, approved for various cancer indications, recorded sales of almost $31.7 billion in 2025, up 7% year over year. Importantly, the company expects the growth to continue till Keytruda loses patent exclusivity in 2028. Keytruda's sales are gaining from rapid uptake across earlier-stage indications. Continued strong momentum in metastatic indications is also boosting sales growth. In 2026, the company expects Keytruda sales to continue to grow. The recent FDA approval of Keytruda and Keytruda Qlex (subcutaneous formulation of Keytruda) for the ovarian cancer indication should contribute to sales growth in 2026, as the drug previously had no approved use in this indicat
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Assessing Merck (MRK) Valuation As Recent Share Price Strength Meets Conflicting Fair Value Views [Yahoo! Finance]Yahoo! Finance
- Merck's KEYTRUDA Combo Wins and Pipeline Shuffle Might Change The Case For Investing In Merck (MRK) [Yahoo! Finance]Yahoo! Finance
- ???????:???????????2035????411.8?????????? ? ???????????????? [CNET News]CNET News
- Big Pharma's next entrant could come from China [Yahoo! Finance]Yahoo! Finance
- Merck Keytruda Combos Strengthen Oncology Platform And Raise Patent Questions [Yahoo! Finance]Yahoo! Finance
MRK
Earnings
- 2/3/26 - Beat
MRK
Sec Filings
- 2/24/26 - Form 10-K
- 2/17/26 - Form 13F-HR
- 2/13/26 - Form 144/A
- MRK's page on the SEC website